-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $322

Benzinga·11/02/2026 14:14:53
Listen to the news
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $288 to $322.